Current stock page

Catalysts

TNDM Stock Catalysts

Earnings · Growth Drivers · Events · AIQ Catalyst

HealthcareMedical - DevicesScore data as of Nov 18, 2026

TNDMTandem Diabetes Care, Inc.

Healthcare / Medical - Devices

Low Priority

In Line With Peers

NeutralEdge 5/10
$17.05−$0.01 (−0.06%)

Latest quote

  • Momentum
    59
  • Value
    64
  • Quality
    51
  • Risk resilience
    38
  • Sentiment
    —
algovestiq.comScore data as of Nov 18, 2026

Stock Catalyst Board

Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.

Next earnings
Feb 18, 2027

Upcoming reporting date available for this company.

AIQ Catalyst
AIQ 55/100

Momentum 59/100 and sentiment — before the next covered event.

Recent coverage
5 articles

Updated Nov 18, 2026 · Sentiment 30.97%

Earnings History And Surprises

See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.

Earnings Expectations And Results

Compare what analysts expected with what the company reported across recent quarters.

Momentum 59/100AIQ Edge 5/10 In Line With Peers
Beat rate
63%
5 of 8 reported periods
Average surprise
+31.3%
Across covered historical reports
Latest result
+59.2%
Nov 5, 2026
EPS estimate versus actual
Actual bars are colored by beat, inline result, or miss.
Earnings history
Report dateFiscal periodEPS estimateEPS actualEPS surpriseRevenue estimateRevenue actual
Nov 5, 2026—-$0.25-$0.10+59.2%$265.84M$283.69M
Aug 6, 2026—-$0.32-$0.31+3.3%$254.99M$254.56M
May 7, 2026—-$0.46-$0.30+34.8%$240.41M$247.22M
Feb 19, 2026—-$0.05-$0.01+80.0%$277.01M$290.38M
Nov 6, 2025—-$0.31-$0.31+0.0%$235.76M$249.25M
Aug 6, 2025—-$0.40-$0.48-20.0%$238.58M$240.68M
Apr 30, 2025—-$0.60-$0.67-11.7%$220.32M$234.42M
Feb 26, 2025—-$0.23$0.01+104.3%$250.58M$252.45M

Analyst Forecast And Price Targets

Wall Street consensus, rating distribution, and the current 12-month target range.

Analyst ratings
Buy
13
Buy
12
Hold
12-month analyst target
$19.00
+11.44% versus current price
Based on 25 analyst observations. Targets are estimates, not predictions.
Low target
$18.00
+5.57% vs latest price
Average target
$19.00
+11.44% vs latest price
High target
$20.00
+17.30% vs latest price

Event Read

Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.

Current event setup

Event dateFeb 18, 2027

Next known earnings or reporting date.

EPS estimate$0.08

Current analyst expectation for the upcoming report.

Revenue estimate$291.52M

Current analyst expectation for the upcoming report.

Sentiment score—

News pressure around the setup.

Momentum score59

Where event reaction would show up first.

AIQ score55/100

Composite decision read before event confirmation.

Analyst context

Consensus
Buy
Analysts
25
Average target
$19.00
Target upside
11.44%
Target range
$18.00 - $20.00

News And Sentiment

Recent company coverage, scored where source sentiment is available.

Positive
4
Neutral
0
Negative
1
zacks.com · Nov 5, 2026

Tandem Diabetes Care, Inc. (TNDM) Reports Q3 Loss, Beats Revenue Estimates

Tandem Diabetes Care (TNDM) delivered earnings and revenue surprises of +62.96% and +6.94%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

gurufocus.com · Sep 30, 2026

TNDM Maintained by Citigroup -- Price Target Lowered to $20

On October 03, 2023, Citigroup maintained a Neutral rating on Tandem Diabetes Care (TNDM) while adjusting its price target down from $24.00 to $20.00, indicatin

gurufocus.com · Sep 28, 2026

Tandem Diabetes (TNDM) Expands Mobi Insulin Delivery System to 12 Countries Outside U.S.

On September 28, 2026, Tandem Diabetes Care Inc (NASDAQ: TNDM) announced the international launch of its Mobi automated insulin delivery device in 12 countries

gurufocus.com · Sep 26, 2026

A Look at Tandem Diabetes Care Inc (TNDM) After 3.3% Gain -- GF Value $24.10 vs Price $15.72

On September 25, 2026, Tandem Diabetes Care Inc (TNDM) shares rose 3.3%, closing at $15.72. This performance is amidst a 52-week range of $11.46 to $29.65, refl

gurufocus.com · Sep 24, 2026

TNDM Maintained by Truist Securities -- Price Target Lowered to $28

Tandem Diabetes Care (TNDM) Analyst Rating Update On October 05, 2023, Tandem Diabetes Care (TNDM) received an updated analyst rating from Truist Securities.

Open full news and sentiment

TNDM Catalysts FAQ

What are the next catalysts for TNDM stock?

TNDM's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.

What upcoming events could move TNDM stock?

Upcoming events that could move TNDM include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.

How could TNDM's next earnings report affect the stock?

TNDM's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.

What could drive TNDM stock higher?

TNDM could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.

What events could hurt TNDM stock?

TNDM could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.